-
公开(公告)号：US20220098165A1
公开(公告)日：2022-03-31
申请号：US17426301
申请日：2020-01-28
Applicant: Heptares Therapeutics Limited
Inventor： Giles Albert Brown , Miles Stuart Congreve , John Andrew Christopher , Nigel Alan Swain , Sarah Joanne Bucknell , Anne Mary Stephenson , Benjamin Gerald Tehan , Geraint Jones , Mark Mills , Anil Patel , Andrew William Phillips
IPC: C07D401/04 , C07D401/14
Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
-
公开(公告)号：US10584111B2
公开(公告)日：2020-03-10
申请号：US16280512
申请日：2019-02-20
Applicant: Heptares Therapeutics Limited
Inventor： John Andrew Christopher , Miles Stuart Congreve , Sarah Joanne Aves , Benjamin Gerald Tehan
IPC: C07D401/04 , C07D403/04 , C07D239/26
Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
-
公开(公告)号：US10166226B2
公开(公告)日：2019-01-01
申请号：US15882038
申请日：2018-01-29
Applicant: Heptares Therapeutics Limited
Inventor： John Andrew Christopher , Miles Stuart Congreve , Sarah Joanne Bucknell , Francesca Deflorian , Mark Pickworth , Jonathan Stephen Mason
IPC: C07D401/14 , A61K31/4709
Abstract: The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
-
公开(公告)号：US20170275265A1
公开(公告)日：2017-09-28
申请号：US15618504
申请日：2017-06-09
Applicant: Heptares Therapeutics Limited
Inventor： John Andrew Christopher , Miles Stuart Congreve , Sarah Joanne Aves , Benjamin Gerald Tehan
IPC: C07D401/04 , C07D239/26 , C07D403/04
CPC classification number: C07D401/04 , C07D239/26 , C07D403/04
Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
-
公开(公告)号：US09688660B2
公开(公告)日：2017-06-27
申请号：US15336893
申请日：2016-10-28
Applicant: Heptares Therapeutics Limited
Inventor： John Andrew Christopher , Miles Stuart Congreve , Sarah Joanne Bucknell , Francesca Deflorian , Mark Pickworth , Jonathan Stephen Mason
IPC: C07D401/14 , A61K31/4709
CPC classification number: A61K31/4709 , C07D401/14
Abstract: The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
-
Patent Agency Ranking
公开(公告)号：US10981889B2
公开(公告)日：2021-04-20
申请号：US16780155
申请日：2020-02-03
Applicant: Heptares Therapeutics Limited
Inventor： John Andrew Christopher , Miles Stuart Congreve , Sarah Joanne Aves , Benjamin Gerald Tehan
IPC: C07D401/04 , C07D403/04 , C07D239/26
Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
-
公开(公告)号：US10246432B2
公开(公告)日：2019-04-02
申请号：US15618504
申请日：2017-06-09
Applicant: Heptares Therapeutics Limited
Inventor： John Andrew Christopher , Miles Stuart Congreve , Sarah Joanne Aves , Benjamin Gerald Tehan
IPC: C07D401/04 , C07D403/04 , C07D239/26
Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
-
公开(公告)号：US20180370961A1
公开(公告)日：2018-12-27
申请号：US15848771
申请日：2017-12-20
Applicant: Heptares Therapeutics Limited
Inventor： Miles Stuart Congreve , John Andrew Christopher , Benjamin Gerald Tehan , Sukhbinder Singh Klair , Sarah Joanne Aves
IPC: C07D417/06 , C07D417/14 , C07D285/24 , C07D513/04 , C07D417/02 , A61K31/549 , C07D417/04
Abstract: The disclosures herein relate to novel compounds of formula wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
-
公开(公告)号：US20180153876A1
公开(公告)日：2018-06-07
申请号：US15882038
申请日：2018-01-29
Applicant: Heptares Therapeutics Limited
Inventor： John Andrew Christopher , Miles Stuart Congreve , Sarah Joanne Bucknell , Francesca Deflorian , Mark Pickworth , Jonathan Stephen Mason
IPC: A61K31/4709
CPC classification number: A61K31/4709 , C07D401/14
Abstract: The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
-
公开(公告)号：US20170239236A1
公开(公告)日：2017-08-24
申请号：US15588051
申请日：2017-05-05
Applicant: Heptares Therapeutics Limited
Inventor： John Andrew Christopher , Miles Stuart Congreve , Sarah Joanne Bucknell , Francesca Deflorian , Mark Pickworth , Jonathan Stephen Mason
IPC: A61K31/4709
CPC classification number: A61K31/4709 , C07D401/14
Abstract: The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.042 seconds)
